1. Search Result
Search Result
Results for "

HBV inhibitor

" in MedChemExpress (MCE) Product Catalog:

156

Inhibitors & Agonists

1

Peptides

29

Natural
Products

7

Isotope-Labeled Compounds

5

Click Chemistry

5

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-155968

    HBV Infection
    HBV-IN-40 (Compound 11826096) is a HBV inhibitor (IC50: 0.7 μM). HBV-IN-40 is an antiviral agent .
    HBV-IN-40
  • HY-161327

    HBV Infection
    HBV-IN-44 (Compound (S)-2a) is a HBV inhibitor with a IC50 value of 23 nM for HbsAg. HBV-IN-44 is less toxic to the neurite growth of HT22 cells and DRG neurons in vitro .
    HBV-IN-44
  • HY-N4168A

    5-O-Caffeoylquinic acid methyl ester

    HBV Infection Cancer
    Neochlorogenic acid methyl ester (5-O-Caffeoylquinic acid methyl ester) is an HBV inhibitor. Neochlorogenic acid methyl ester can be isolated from L. japonica flower buds with potent HBV inhibitory activity .
    Neochlorogenic acid methyl ester
  • HY-157993

    HBV Infection
    SAG-524 is a potent oral small molecule HBV viral replication inhibitor. SAG-524 decreased HBV-DNA and HbsAg levels in supernatant of HepG2.2.15 cells, IC50 0.92 and 1.4 nM, respectively .
    SAG-524
  • HY-N3609

    HBV Infection
    Coclauril is an inhibitor of HBV. Coclauril inhibits HBV replication in the human hepatoblastoma cell line with an EC50 of 7.6 μg/mL .
    Coclauril
  • HY-W060316

    3-Hydroxy-5-isopropyltropolone

    HBV DNA/RNA Synthesis Infection
    β-Thujaplicinol (3-Hydroxy-5-isopropyltropolone) is an inhibitor of hepatitis B virus (HBV) ribonuclease H. β-Thujaplicinol inhibits RNAseHs of HBV genotypes D and H with IC50 values of 5.9 and 2.3 μM, respectively .
    β-Thujaplicinol
  • HY-116607

    HBV Infection
    BAY38-7690 is a non-nucleoside inhibitor that inhibits HBV replication. BAY38-7690 inhibits viral DNA replication by preventing the formation of viral core particles (nucleocapsids). The IC50 value of BAY38-7690 against HBV in stably transfected HepG2.2.15 cells is 0.15 μM .
    BAY38-7690
  • HY-117999

    HBV Infection
    BAY39-5493 is a non-nucleoside inhibitor that inhibits HBV replication. BAY39-5493 inhibits viral DNA replication by preventing the formation of viral core particles (nucleocapsids). The IC50 value of BAY39-5493 against HBV in stably transfected HepG2.2.15 cells is 0.03 μM .
    BAY39-5493
  • HY-N2882

    HBV Infection
    Apigenin-4'-α-L-rhamnoside is a potent inhibitor of HBV. Apigenin-4'-α-L-rhamnoside inhibits the secretory level of HBV surface antigen (HBsAg) in HepG2.2.15 cells .
    Apigenin-4'-α-L-rhamnoside
  • HY-168045

    HBV DNA/RNA Synthesis Infection
    HBV-IN-48 is an HBV inhibitor. HBV-IN-48 has antiviral activity against HBV in HepDE19 cells, with an EC50 value of 0.005 μM. HBV-IN-48 can reduce serum HBV DNA levels in mouse models of HBV infection .
    HBV-IN-48
  • HY-N12483

    HBV Infection
    Catenulopyrizomicin A has a thiazolyl pyridine moiety. Catenulopyrizomicin A can be isolated from the fermentation broth of rare actinomycete Catenuloplanes sp. Catenulopyrizomicin A has anti-Hepatitis B virus activity .
    Catenulopyrizomicin A
  • HY-146395

    HBV DNA/RNA Synthesis Apoptosis Infection Cancer
    HBV-IN-23 (Compound 5k) is an inhibitor of HBV DNA replication with an IC50 of 0.58 μM. HBV-IN-23 inhibits HBV DNA replication in both agent sensitive and resistant HBV strains. HBV-IN-23 shows anti-hepatocellular carcinoma cell (HCC) activities. HBV-IN-23 induces HepG2 cells apoptosis .
    HBV-IN-23
  • HY-169125

    HBV Infection
    HBV-IN-49 is an anti-hepatitis B virus (HBV) agent that inhibits HBV replication. HBV-IN-49 can be utilized in infection research .
    HBV-IN-49
  • HY-163580

    HBV Infection Inflammation/Immunology
    HBV/HDV-IN-3 (Compd 1) is a dual HBV and HDV inhibitor, with an EC50 of <50 nM against HBV .
    HBV/HDV-IN-3
  • HY-163581A

    HBV Infection Inflammation/Immunology
    HBV/HDV-IN-4 hydrochloride (Compd 4) is a dual HBV and HDV inhibitor, with an EC50 of <50 nM against HBV .
    HBV/HDV-IN-4 hydrochloride
  • HY-149392

    HBV Infection
    HBV-IN-35 (Compound 88) is a HBV inhibitor. HBV-IN-35 has anti-HBV activities in mouse and human hepatocytes (EC50: 100 nM and 400 nM respectively) .
    HBV-IN-35
  • HY-149815

    HBV Infection Inflammation/Immunology
    HBV-IN-33 (C-49), a HBV inhibitor, notably suppresses HBV replication in HepAD38, HepG2-HBV1.3 and HepG2-NTCP cells .
    HBV-IN-33
  • HY-149357

    HBV Infection
    Yhhu6669 is an anti-HBV agent. Yhhu6669 inhibits HBV DNA. Yhhu6669 inhibits HBV replication by inducing the formation of DNA-free capsids. Yhhu6669 decreases HBV DNA and HBcAg in AAV/HBV-infected mice. Yhhu6669 has favorable PK properties .
    Yhhu6669
  • HY-156703S

    HBV Infection
    HBV-IN-39-d3 (Example 14) is a deuterated HBV-IN-39 (Example 13). HBV-IN-39 is an HBV inhibitor. HBV-IN-39-d3 has better oral bioavailability than HBV-IN-39 .
    HBV-IN-39-d3
  • HY-148782

    HBV Infection
    HBV-IN-31 is a potent cccDNA (covalently closed circular DNA) inhibitor. HBV-IN-31 shows anti-HBV activity with an IC50 value of 0.13 µM for HBsAg. HBV-IN-31 inhibits cell growth .
    HBV-IN-31
  • HY-148783

    HBV Infection
    HBV-IN-32 is a potent cccDNA (covalently closed circular DNA) inhibitor. HBV-IN-32 shows anti-HBV activity with an IC50 value of 0.14 µM for HBsAg. HBV-IN-32 inhibits cell growth .
    HBV-IN-32
  • HY-163124

    HBV Infection
    HBV-IN-43 (compound 5832) is a potent inhibitor of HBV .
    HBV-IN-43
  • HY-156665

    HBV Infection
    HBV-IN-37 is an inhibitor of HBV with an EC50 value of 10 μM .
    HBV-IN-37
  • HY-159160

    HBV Infection
    HBV-IN-46 (compound 1.6) is an active metabolite. HBV-IN-46 is a HBV S-antigen inhibitor, with an EC50 of 2.6 nM .
    HBV-IN-46
  • HY-131343

    HBV DNA/RNA Synthesis Infection
    HBV-IN-4, a phthalazinone derivative, is a potent and orally active HBV DNA replication inhibitor with an IC50 of 14 nM. HBV-IN-4 induces the formation of genome-free capsids and has potent anti-HBV potencies .
    HBV-IN-4
  • HY-156702

    HBV Infection
    HBV-IN-38 (Example 193) is an HBV DNA inhibitor (EC50≤100nM). HBV-IN-38 can be used to study viral infections .
    HBV-IN-38
  • HY-155547

    HBV Infection
    HBV-IN-34 (compound 17i) is a potent HBsAg production inhibitor. HBV-IN-34 exhibits excellent in vitro anti-HBV potency, with an EC50 of 0.018 μM and 0.044 μM for HBV DNA and HBsAg, respectively .
    HBV-IN-34
  • HY-146011

    HBV DNA/RNA Synthesis Infection
    HBV-IN-21 (Compound II-8b) is an HBV DNA replication inhibitor with an IC50 of 2.2 µM. HBV-IN-21 can interact HBV 4 capsid protein with good affinity (KD = 60.0 μM) .
    HBV-IN-21
  • HY-145872

    HBV Infection
    HBV-IN-20 is a potent and oral active HBV inhibitor with an EC50 of 0.46 µM. HBV-IN-20 is a typical type II CpAM (core protein assembly modulators) .
    HBV-IN-20
  • HY-145049

    HBV Infection
    HBV-IN-6 is a potent HBV inhibitor with an EC50 of 44 nM (WO2021213445A1, compound 3) .
    HBV-IN-6
  • HY-145050

    HBV Infection
    HBV-IN-7 is a potent HBV inhibitor with an EC50 of 7 nM (WO2021213445A1, compound 5) .
    HBV-IN-7
  • HY-149476

    Lipoxygenase Neurological Disease
    5-LOX-IN-5 (Compound 29) is a 5-LOX inhibitor (IC50: 56 nM). 5-LOX-IN-5 can be used for research of neurodegenerative diseases .
    5-LOX-IN-5
  • HY-163516

    HBV Infection
    HBV-IN-45 is a selective and orally active HBV capsid assembly modulator with an IC50 of 0.51 μM for HBcAg in HBC cells. HBV-IN-45 shows potent anti-HBV activities .
    HBV-IN-45
  • HY-145051

    HBV Infection
    HBV-IN-8 is a potent HBV inhibitor with an EC50 of 287.9 nM (WO2021213445A1, compound 13) .
    HBV-IN-8
  • HY-117650A
    RG7834
    5 Publications Verification

    RO 7020322

    HBV Infection
    RG7834 (RO 7020322) is a highly selective and orally bioavailable HBV inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells .
    RG7834
  • HY-148348

    HBV Infection
    AB-836 is an orally active HBV capsid inhibitor. AB-836 inhibits viral replication by interacting with HBV core protein .
    AB-836
  • HY-147863

    HBV Infection Neurological Disease
    HBV-IN-24 (compound (2ʹS, 6S)-1a) is a potent HBV inhibitor. HBV-IN-24 exhibits potent inhibition activity against HBV DNA, HBsAg, and HBeAg, with EC50 values of 0.6, 0.6, and 4.6 nM, respectively. HBV-IN-24 shows excellent antiviral activity, could have improved neurotoxicity .
    HBV-IN-24
  • HY-146394

    HBV DNA/RNA Synthesis Infection
    HBV-IN-22 (Compound LC5f) is an inhibitor of HBV DNA replication with IC50 values of 0.71 μM and 0.84 μM against wild-type and agent resistant HBV strains, respectively .
    HBV-IN-22
  • HY-P3465
    Bulevirtide
    1 Publications Verification

    Myrcludex B

    HBV Infection
    Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosis research .
    Bulevirtide
  • HY-145052

    HBV Infection
    HBV-IN-9 is a potent HBsAg (HBV Surface antigen) inhibitor (IC50=10 nM) and HBV DNA production inhibitor (IC50=0.15 nM in HepG2.2.15 cells) . From patent WO2018001952A1, example 20.
    HBV-IN-9
  • HY-N10404

    HBV Inflammation/Immunology
    Junceellolide C is a transcription inhibitor of cccDNA. Junceellolide C inhibits HBV DNA replication and significantly decreases the level of supernatant HBV RNA with EC50 values of 5.19, 3.52 μM respectively in HepAD38 cells. Junceellolide C is a potent anti-HBV agent .
    Junceellolide C
  • HY-145871

    HBV Infection
    BA38017 is a potent HBV core protein assembly modulator. BA38017 inhibits HBV replication with an EC50 of 0.20 μM .
    BA38017
  • HY-144047

    HBV DNA/RNA Synthesis Infection
    HBV-IN-16 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-16 is a quinoline derivative. HBV-IN-16 has the potential for the research of HBV infection (extracted from patent WO2019121357A1, compound 1) .
    HBV-IN-16
  • HY-144045

    HBV DNA/RNA Synthesis Infection
    HBV-IN-14 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-14 is a pyridinopyrimidinones compound. HBV-IN-14 has the potential for the research of HBV infection (extracted from patent WO2021190502A1, compound 5) .
    HBV-IN-14
  • HY-144046

    HBV DNA/RNA Synthesis Infection
    HBV-IN-15 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-15 is a flavone derivative. HBV-IN-16 has the potential for the research of HBV infection (extracted from patent WO2020052774A1, compound 2) .
    HBV-IN-15
  • HY-156272

    HBV Infection
    HBV-IN-41 (compound 45) is a potent and orally active Hepatitis B Virus (HBV) inhibitor, with an EC50 of 0.027μM .
    HBV-IN-41
  • HY-109969

    HBV Infection
    Z060228 is a capsid-targeting anti-HBV agent that inhibits HBV DNA replication in the supernatant of the HepG2.2.15 cell .
    Z060228
  • HY-148768

    HBV Inflammation/Immunology
    AB-506 is an orally active inhibitor of HBV replication targeting the viral core protein. AB-506 can bind to HBV core protein, accelerate capsid assembly and inhibit HBV pgRNA encapsidation. AB-506 can be used in chronic hepatitis B (CHB) research .
    AB-506
  • HY-W676876

    HBV Infection
    Oxynitidine is an HBV inhibitor (ID50=30.8 µg/mL), which can effectively inhibit the DNA replication activity of HBV. Oxynitidine can be used in the study of viral infections .
    Oxynitidine
  • HY-148781

    HBV Infection
    HBV-IN-30 (ex44), a flavone derivative, is a potent covalently closed circular DNA (cccDNA) inhibitor. cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-30 has the potential for the research of HBV infection .
    HBV-IN-30

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: